NASDAQ$CLDX
Celldex Therapeutics Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Celldex reported Q4 2019 results with a net loss, but is advancing its pipeline programs.
Celldex Therapeutics reported a net loss for Q4 2019, but is making progress with its CDX-1140, CDX-3379, and CDX-0159 programs. The company believes its cash position is sufficient to fund operations into the first quarter of 2021.
- Celldex entered 2020 with momentum due to promising CDX-1140 data.
- Patient recruitment is ongoing across multiple CDX-1140 expansion cohorts.
- Dosing was completed in the Phase 1 healthy volunteer study of CDX-0159.
- Celldex is preparing to advance CDX-527 into the clinic.
Headline financials
Revenue & EPS history
Celldex · Revenue · Quarterly
$887K
Forward guidance
Celldex believes that its current cash, cash equivalents, and marketable securities are sufficient to fund planned operations into the first quarter of 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
+1.3%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+1.7%
Avg return
30 days after
59%
38 / 64 earnings
Positive
+35.2%
Q4 2023
Best reaction
-21.5%
Q3 2014
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.2% | -7.0% | -16.8% | |
| Q4 2025 | -0.6% | -6.1% | -1.7% | |
| Q3 2025 | +7.6% | +12.7% | +23.2% | |
| Q1 2025 | +2.2% | -0.4% | -0.5% | |
| Q4 2024 | -1.6% | -3.1% | -3.4% | |
| Q3 2024 | +4.1% | +3.1% | +5.3% | |
| Q2 2024 | +2.7% | +3.8% | +36.5% | |
| Q1 2024 | -0.8% | -6.2% | -22.4% | |
| Q4 2023 | +35.2% | +37.4% | +10.7% | |
| Q3 2023 | +10.2% | +23.1% | +35.9% | |
| Q2 2023 | -6.5% | -7.4% | -13.3% | |
| Q1 2023 | +5.8% | +5.3% | +5.5% | |
| Q4 2022 | +7.9% | +8.7% | -17.4% | |
| Q3 2022 | +9.4% | +5.6% | +7.5% | |
| Q2 2022 | -3.8% | +1.7% | -17.7% | |
| Q1 2022 | -10.3% | -10.6% | -23.4% | |
| Q4 2021 | +4.7% | +0.5% | +14.7% | |
| Q3 2021 | +0.6% | -7.6% | -18.1% | |
| Q2 2021 | +6.2% | +3.7% | +20.9% | |
| Q1 2021 | -1.3% | -3.3% | +0.8% | |
| Q4 2020 | -16.9% | -4.0% | +30.4% | |
| Q3 2020 | +1.4% | +9.6% | +10.3% | |
| Q2 2020 | -3.5% | -12.3% | -7.5% | |
| Q1 2020 | +0.4% | +0.4% | +29.4% | |
| Q4 2019 | +3.4% | -7.3% | +68.2% | |
| Q3 2019 | -2.5% | -5.0% | -7.9% | |
| Q2 2019 | +6.2% | +1.4% | +2.9% | |
| Q1 2019 | -6.6% | -15.4% | -36.1% | |
| Q4 2018 | +9.0% | +4.3% | -7.3% | |
| Q3 2018 | +15.2% | +3.0% | -21.2% | |
| Q2 2018 | +0.0% | -6.7% | +2.2% | |
| Q1 2018 | -5.2% | -7.8% | -15.6% | |
| Q4 2017 | +14.1% | +17.0% | -17.4% | |
| Q3 2017 | +15.5% | +14.7% | +23.1% | |
| Q2 2017 | +2.4% | -0.8% | +11.7% | |
| Q1 2017 | +0.7% | +2.9% | -23.5% | |
| Q4 2016 | +1.8% | +2.1% | -2.1% | |
| Q3 2016 | +22.3% | +39.8% | +21.7% | |
| Q2 2016 | +0.4% | -4.3% | -21.5% | |
| Q1 2016 | -8.9% | — | — | |
| Q4 2015 | +10.9% | — | — | |
| Q3 2015 | +5.4% | — | — | |
| Q2 2015 | -21.4% | — | — | |
| Q1 2015 | +0.3% | — | — | |
| Q4 2014 | +0.9% | — | — | |
| Q3 2014 | -21.5% | — | — | |
| Q2 2014 | +4.0% | — | — | |
| Q1 2014 | -3.3% | — | — | |
| Q4 2013 | -5.2% | — | — | |
| Q3 2013 | +4.2% | — | — | |
| Q2 2013 | -6.7% | — | — | |
| Q1 2013 | +2.5% | — | — | |
| Q4 2012 | +13.3% | — | — | |
| Q3 2012 | +5.9% | — | — | |
| Q2 2012 | -2.6% | — | — | |
| Q1 2012 | +1.5% | — | — | |
| Q4 2011 | +2.6% | — | — | |
| Q3 2011 | -3.6% | — | — | |
| Q2 2011 | -15.9% | — | — | |
| Q1 2011 | +0.5% | — | — | |
| Q4 2010 | -5.4% | — | — | |
| Q3 2010 | +7.6% | — | — | |
| Q2 2010 | -3.9% | — | — | |
| Q1 2010 | -2.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro